
Amgen
AMGN · NASDAQ · Biotechnology
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $252 bn
- Div. yield
- 3,2%
- Year to date
- +42,7%
Ratio score
based on 9 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
4 ✓ · 4 — · 1 ✕ · 1 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 26,8 | 22,6 | 42,1 |
| Forward P/E | 19,2 | — | 18,7 |
| PEG | 5,9 | — | 4,1 |
| P/S | 6,5 | 4,9 | 6,6 |
| EV/EBITDA | 18,2 | 14,3 | 28,2 |
| P/FCF | 24,8 | — | 26,0 |
| P/B | 17,6 | 23,4 | 9,8 |
Industry median — across 6 profitable companies in “Biotechnology” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 42 analysts
- Buy
- 18
- Hold
- 20
- Sell
- 4
Beat the EPS forecast in 4 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q3 2026 | 5,91 | 6,45 | Up +9,2% |
| Q2 2026 | 5,73 | 6,29 | Up +9,8% |
| Q1 2026 | 4,85 | 5,15 | Up +6,1% |
| Q4 2025 | 4,83 | 5,29 | Up +9,6% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10,4 bn | 10,1 bn | 8,62 bn | 9,87 bn | 9,56 bn | 9,18 bn | 8,15 bn | 9,09 bn | 8,50 bn | 8,39 bn | 7,45 bn | 8,20 bn |
| EPS | 7,08 | 4,37 | 3,34 | 2,46 | 5,93 | 2,65 | 3,20 | 1,16 | 5,22 | 1,38 | −0,21 | 1,43 |
| Margin | 37,3% | 23,6% | 21,1% | 13,5% | 33,7% | 15,6% | 21,2% | 6,9% | 33,3% | 8,9% | −1,5% | 9,4% |
| FCF | 3,65 bn | 3,49 bn | 1,48 bn | 961 m | 4,25 bn | 1,91 bn | 980 m | 4,40 bn | 3,31 bn | 2,22 bn | 459 m | 289 m |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: no purchases, sales $26,7 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| khosla rachna13 Aug 2026 · sale | $521 365 | 1 252 | $416,43 |
| khosla rachna11 Aug 2026 · sale | $825 134 | 2 000 | $412,57 |
| miller derek6 Aug 2026 · sale | $733 033 | 1 821 | $402,54 |
| miller derek6 Aug 2026 · sale | $832 864 | 2 069 | $402,54 |
| grygiel nancy a.6 Aug 2026 · sale | $402 160 | 1 000 | $402,16 |
| grygiel nancy a.6 Aug 2026 · sale | $792 255 | 1 970 | $402,16 |
| grygiel nancy a.4 May 2026 · sale | $400 451 | 1 237 | $323,73 |
| santos esteban26 Feb 2026 · sale | $9,21 m | 24 291 | $379,12 |
| santos esteban26 Feb 2026 · sale | $11,6 m | 30 501 | $379,12 |
| busch matthew c.19 Feb 2026 · sale | $375 790 | 1 000 | $375,79 |
| grygiel nancy a.20 Nov 2025 · sale | $552 773 | 1 639 | $337,26 |
| grygiel nancy a.20 Nov 2025 · sale | $505 894 | 1 500 | $337,26 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- US
- IPO date
- 17 Jun 1983
- Website
- www.amgen.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
GILDGilead Sciences | $167,58 | 25★★★★★★★would not consider | — | +6,5% | −12,5% |
VRTXVertex Pharmaceuticals | $537,79 | 72★★★★★★★★★would consider | 33,7 | +10,5% | 30,7% |
ABBVAbbVie | $294,55 | 72★★★★★★★★★would consider | 50,4 | +10,7% | 15,7% |
REGNRegeneron Pharmaceuticals | $952,40 | 67★★★★★★★★★would watch | 20,5 | +18,6% | 28,5% |
MRNAModerna | $215,27 | 22★★★★★★would not consider | — | +13,1% | −110,5% |
Ratio — a score by our methodology, not an investment recommendation.




